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Malaria is the most important parasitic disease of man,
exacting an estimated toll of 300–500·million new
infections and 1.5–3·million deaths annually (World Health
Organization, 2002). Moreover, recent analyses suggest that
the medical impact of malaria has actually been significantly
underestimated (Breman, 2001) and that the enormous
economic impact of malaria has never been adequately
considered (Gallup and Sachs, 2001). The profile of increasing
resistance of the Plasmodium spp. parasite to
chemoprophylactic and chemotherapeutic agents, the
increasing resistance of the Anopheles spp. vector to
insecticides, and the inability of the most affected countries to
mobilize and sustain the resources required for malaria control,
highlight the critical need for an effective vaccine against this
disease. 
The development of a malaria vaccine is, however, a
formidable challenge. Despite a relatively intense and
systematic research effort conducted since the 1960s and
clinical trials of a large number of candidate vaccines with a
range of delivery systems designed to induce protective
antibody or cell-mediated immune responses against the
sporozoite in circulation, the infected hepatocyte or the
parasitized erythrocyte, few humans have been protected
(reviewed in Richie and Saul, 2002). Even in animal models,
vaccines have not been optimal. As compared to developing
vaccines against viruses and bacteria, developing a vaccine
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Recent advances in the fields of genomics, proteomics
and molecular immunology offer tremendous
opportunities for the development of novel interventions
against public health threats, including malaria. However,
there is currently no algorithm that can effectively identify
the targets of protective T cell or antibody responses from
genomic data. Furthermore, the identification of antigens
that will stimulate the most effective immunity against
the target pathogen is problematic, particularly if the
genome is large. Malaria is an attractive model for the
development and validation of approaches to translate
genomic information to vaccine development because of
the critical need for effective anti-malarial interventions
and because the Plasmodium parasite is a complex multi-
stage pathogen targeted by multiple immune responses.
Sterile protective immunity can be achieved by
immunization with radiation-attenuated sporozoites, and
anti-disease immunity can be induced in residents in
malaria-endemic areas. However, the 23·Mb Plasmodium
falciparum genome encodes more than 5300 proteins, each
of which is a potential target of protective immune
responses. The current generation of subunit vaccines is
based on a single or few antigens and therefore might
elicit too narrow a breadth of response. We are working
towards the development of a new generation vaccine
based on the presumption that duplicating the protection
induced by the whole organism may require a vaccine
nearly as complex as the organism itself. Here, we present
our strategy to exploit the genomic sequence of P.
falciparum for malaria vaccine development. 
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against malaria is complicated by the complexity of the
parasite as well as the complexity of the host’s response to the
parasite. Challenges include the complex multi-stage parasite
life cycle, a large 23·Mb genome encoding more than 5300
proteins, distinct stage-specific expression of the proteins, the
requirement for distinct immune mechanisms targeting these
different stages, the poor understanding of the protective
immune mechanisms, allelic heterogeneity of parasite antigens
between strains, antigenic variation within a single strain,
sequence polymorphism of critical target epitopes, parasite
evasion of host immune responses, and variant disease
expression based on epidemiology, transmission dynamics and
the genetic background and age of the host (Hoffman et al., in
press).
Models demonstrating the feasibility of developing a
malaria vaccine
The feasibility of developing a malaria vaccine is,
nonetheless, suggested by two human models demonstrating
that protective immunity can be induced by exposure to intact
Plasmodium falciparum parasites. 
Model 1. Sterile protective immunity
One model, immunization with radiation-attenuated
sporozoites, is for the design of a vaccine to prevent all clinical
manifestations of malaria (reviewed in Hoffman et al., 2002a).
In 1967, it was demonstrated that mice immunized with
Plasmodium berghei sporozoites, attenuated by exposure to x-
ray or gamma-radiation such that they could invade the host
hepatocyte and undergo limited development but could not
mature into blood-stage parasites, were protected against
challenge with infectious sporozoites (Nussenzweig et al.,
1967). Since the parasite was unable to mature to the
erythrocytic stage, clinical symptoms of disease and
transmission of malaria did not occur. Immunization with heat-
killed, formalin-inactivated or lysed sporozoites was not
effective, but protective immunity could be induced in mice
immunized with infectious sporozoites and treated with
chloroquine to prevent erythrocyte infection. These data
emphasize the requirement for live sporozoites targeting the
liver. In 1973, it was demonstrated that human volunteers
could be protected against P. falciparum sporozoite challenge
by immunization with radiation-attenuated P. falciparum
sporozoites (Clyde et al., 1973a,b). It is now well established
that immunization of mice or humans with radiation-attenuated
Plasmodium sporozoites confers sterile protective immunity
against challenge with infectious, non-attenuated sporozoites
in virtually all recipients (reviewed in Nussenzweig and
Nussenzweig, 1989; Hoffman et al., 2002a). This protection is
effective against challenge with massive doses of infectious
sporozoites, is species-specific but not strain-specific, is
efficacious in outbred and inbred mouse strains differing in
genetic background, as well as major histocompatibility
complex (MHC)-diverse humans, and persists for at least
9·months in humans. The importance of immune mechanisms
that are active in the irradiated sporozoite model is highlighted
by the fact that infection-blocking immunity in humans rarely,
if ever, occurs under natural conditions. 
The Plasmodium spp. parasite developing within the host
hepatocyte is the major target of protective immune responses
induced by immunization with irradiated sporozoites. CD8+ T
cells specific for peptide epitopes from proteins expressed by
irradiated sporozoites in the hepatocyte are considered the
primary immune effectors, and protection is mediated by
interferon g (IFN-g ) released by these CD8+ T cells (as well as
other cells) rather than by direct cytotoxic T cell-mediated lysis
(Doolan and Hoffman, 1999, 2000; Good and Doolan, 1999;
Plebanski and Hill, 2000). CD4+ T cells that recognize
parasite-derived peptide/class II MHC molecule complexes on
the hepatocyte, as well as antibodies against sporozoite surface
proteins that neutralize the infectivity of sporozoites for
hepatocytes, may also play a role (reviewed in Sinnis and
Nussenzweig, 1996; Good and Doolan, 1999). The targets of
cellular immunity (both at the CD8+ and CD4+ T cell level)
are largely unknown, however, and correlates of protection
after sporozoite immunization are unclear. Also, it is not
established whether the protective immune responses induced
by immunization with irradiated sporozoites are narrowly
focused on a few immunodominant antigens and epitopes or,
alternatively, are broadly dispersed on a relatively large
number of parasite antigens. Recently, we have demonstrated
that 16 of 27 putative P. falciparum proteins identified by
multidimensional protein identification technology (MudPIT)
were recognized by volunteers immunized with irradiated
sporozoites; nine proteins were highly antigenic, three were
of intermediate reactivity, and four were weakly antigenic
(Doolan et al., 2003). These data support our contention that
protective immune responses induced by immunization with
irradiated sporozoites are probably directed against multiple
antigens, and against multiple epitopes on those antigens, with
variable potency. Thus, a multi-antigen vaccine that induces
CD8+ as well as CD4+ T cell responses against liver-stage
antigens may be required to mimic the breadth and complexity
of the irradiated sporozoite-induced protection. 
The induction of sterile immunity in humans by
immunization with radiation-attenuated P. falciparum
sporozoites provides proof-of-principle regarding the
feasibility of a malaria vaccine that prevents blood-stage
infection and clinical disease. This model also suggests a
logical approach for making such a vaccine: identify the
antigenic targets of irradiated sporozoite-induced immunity
(those antigens expressed by irradiated sporozoites within
hepatocytes that are recognized by sporozoite-induced T cell
responses) and package these antigens or their critical minimal
epitopes in a vaccine formulation that is immunogenic and
suitable for manufacture and administration. 
Model 2. Anti-disease immunity
The second model is that of naturally acquired immunity,
for the design of a vaccine to prevent death and severe disease.
In areas where malaria is transmitted, individuals that survive
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past a certain age will become reinfected and will become
clinically ill but will not develop severe disease or die. In areas
with annual, stable transmission, there is little to no severe
disease or malaria-associated deaths after the age of
7–10·years; in areas with very intense transmission, this
transition may occur as early as the second or third year of life.
The decrease in the incidence of P. falciparum infections, the
prevalence and density of parasitemia, and the morbidity and
mortality associated with Plasmodium spp. infection with
natural exposure is consistent with acquisition of anti-malarial
immunity in humans (Baird, 1995, 1998; Snow et al., 1998).
Moreover, passive transfer of purified immunoglobulin derived
from adults with naturally acquired immunity following
lifelong exposure to endemic malaria results in a marked
decrease in P. falciparum blood-stage parasitemia and
resolution of symptoms in the recipients (Cohen et al., 1961;
McGregor and Carrington, 1963; Sabchareon et al., 1991). A
clinically important degree of erythrocytic stage immunity can
be also induced by repeated experimental exposure to blood-
stage infection (reviewed in Jeffery, 1966; Collins and Jeffery,
1999a,b). 
In naturally acquired immunity, all arms of the immune
system are probably activated against all stages of the parasite
life cycle. However, most malariologists believe that the most
important effectors in naturally acquired immunity are
antibodies directed against parasite proteins expressed on the
surface of erythrocytes that prevent sequestration in the
microcirculation (Duffy et al., 2001), antibodies directed
against parasite proteins expressed on the surface of merozoites
that prevent invasion of erythrocytes (Sim et al., 2001), and
antibodies expressed against either type of parasite protein
that are capable of mediating antibody-dependent cellular
inhibition (Bouharoun-Tayoun et al., 1995), whereby
biologically active molecules, including cytokines, nitric
oxide and free oxygen intermediates, are released from
reticuloendothelial or other cells after activation through the Fc
component of the bound antibody molecule. Furthermore,
pathogenesis of the clinical disease (Miller et al., 1994; Marsh
et al., 1996; Clark and Schofield, 2000) may be mediated by
these same host-derived biologically active molecules or by
putative toxins released from the infected erythrocytes
(Playfair, 1996; Clark and Schofield, 2000; Schofield et al.,
2002), and neutralization of these via antibodies may play
a role in protection. Finally, antibody responses against
sporozoites as well as T cell responses against parasite proteins
expressed within infected hepatocytes probably also contribute
to naturally acquired disease modulating immunity. By
reducing the number of Plasmodium spp. parasites maturing
within the host hepatocyte, these pre-erythrocytic stage
immune responses would be expected to dramatically reduce
the initial blood-stage parasite burden and consequently the
magnitude of the subsequent asexual stage amplification. In
both hospitalized populations and semi-immune populations,
most investigators have demonstrated a direct correlation
between P. falciparum parasite density and morbidity and
mortality associated with P. falciparum infection (McElroy et
al., 1994, 1997; Mbogo et al., 1995; Vounatsou et al., 2000).
The critical antigens targeted by naturally acquired immune
responses are yet to be defined. Given the complexity of the
parasite, and the host, it is likely that tens, hundreds or even
thousands of parasite proteins may be targeted. This breadth of
response may be further expanded by exposure to many
heterogeneous parasite strains.
The existence of naturally acquired immunity and the
demonstrations that a clinically important degree of
erythrocytic stage immunity can be induced by experimental
(Jeffery, 1966; Collins and Jeffery, 1999a,b) or natural (Baird,
1995, 1998) exposure to repeated blood-stage infection provide
a strong rationale for the identification of the antigenic targets
of naturally acquired immunity (those antigens expressed on
the surface of merozoites or infected erythrocytes or in apical
organelles that are recognized by antibodies induced in the
context of naturally acquired immunity) and the development
of vaccines designed to induce high levels of antibody
responses against these antigens.
Current approaches to malaria vaccine development 
Based on the two human models for malaria vaccine
development described above, we consider that there are two
extremes of vaccine design: (1) induction of T cell-mediated
immune responses, directed against parasite antigens
expressed by irradiated sporozoites within hepatocytes (liver-
stage antigens) and (2) induction of antibody responses
directed against parasite proteins expressed on the surface of
merozoites or infected erythrocytes or in apical organelles.
Thus, a two-tiered approach to malaria vaccine development is
likely to be the most effective. Induction of T cell responses
against liver-stage antigens would destroy the majority of
parasites during the five-day window of hepatic stage
development. However, since each sporozoite can potentially
develop into 10·000–30·000 merozoites, each of which may
potentially undergo a series of asexual amplifications resulting
in a 10–20-fold increase in the number of parasites in the
bloodstream every 48·h, a hepatic-stage vaccine must be 100%
effective. Induction of antibody responses against erythrocytic
stage antigens would protect against severe disease and death
in individuals who experience breakthrough blood-stage
infections.
Our hypothesis is that by reducing the number of parasites
emerging from the liver (via T cell immune responses directed
against those antigens expressed by irradiated sporozoites in
hepatocytes) and priming the immune system to erythrocytic
stage antigens that will be boosted by infection from natural
exposure (via antibody responses directed against parasite
proteins expressed on the surface of merozoites or infected
erythrocytes or apical organelles), one will reduce the severity
and mortality of P. falciparum malaria.
Most current candidate malaria vaccines are designed to
induce protective immune responses against pre-erythrocytic
and/or erythrocytic stage antigens. Another type of vaccine
being developed, a transmission-blocking vaccine, is designed
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to protect the entire community rather than the immunized
individual, by inducing protective antibodies against sexual
stage antigens and thereby reducing the intensity of malaria
transmission.
Two main approaches to malaria vaccine development are
currently being pursued worldwide. The most work has been
done, and progress achieved, on an approach focused on
maximizing the magnitude and quality of immune responses
to a single or a few key antigens, such as the P. falciparum
circumsporozoite protein (CSP) or merozoite surface
protein 1 (MSP1), by immunizing with synthetic peptides or
recombinant proteins in an adjuvant (Mahanty et al., 2003).
These vaccines are being designed to primarily induce
antibody and CD4+ T cell responses, but there is also interest
in eliciting CD8+ T cell responses. Researchers focusing on
this approach consider that the subset of parasite antigens
currently identified as potential vaccine targets are adequate,
that any one given antigen is likely to be as good as another
provided that it is expressed in an appropriate context and that
the major obstacle to fielding an effective vaccine lies with
optimizing the induction of the desired immune response by
vaccination. Some success with this approach has been shown
with the demonstration that a CSP-based vaccine formulated
in a strong adjuvant can provide short-term protection of
malaria-naïve volunteers against experimental challenge and of
semi-immune adults against naturally transmitted malaria.
However, the transient nature of this protection and the
inability of the vaccine to induce the class I-restricted
responses considered important for pre-erythrocytic stage
protection (Lalvani et al., 1999) show that the vaccine is far
from adequate as currently formulated. The questions of
whether all antigens are the same and it is the vaccine delivery
system that matters, whether the single ‘key’ antigen has
already been identified or whether there is a single ‘key’
antigen that has not yet been identified remain. 
The second approach to malaria vaccine development is to
focus on all of the currently known, promising candidate
antigens and to induce good immune responses against them;
for example, by priming with plasmid DNA and then boosting
with DNA, recombinant viruses or recombinant proteins. The
goal is to elicit CD8+ and CD4+ T cell as well as antibody
responses. Researchers focusing on this multi-valent, multi-
immune response approach are skeptical about the ability of a
vaccine based on a single antigen to protect against a parasite
as complex as Plasmodium that, as evidenced by its ability to
establish a chronic, recrudescing infection, has evolved
mechanisms for resisting all arms of the host immune response.
Furthermore, genetic restriction of the host immune response
and parasite variation of target antigens and epitopes pose
enormous obstacles for vaccine development. That a
multivalent approach may be more successful than an approach
based on a single or few antigens is supported by the
experimental demonstration that immunization of mice with a
mixture of DNA vaccines encoding two pre-erythrocytic stage
antigens could circumvent the genetic restriction of protection
seen with each vaccine alone and could confer additive
protection in some genetically distinct mouse strains not
protected or poorly protected by either of the individual
vaccines (Doolan et al., 1996). Additional support is provided
by recent data demonstrating enhanced protection with a
tetravalent Plasmodium knowlesi vaccine as compared with
vaccines based on only one or two of the four antigens (W. R.
Weiss, unpublished results). Thus, researchers pursuing this
second approach are focusing their efforts on the development
of a multi-valent, multi-stage and multi-immune response
vaccine (Doolan and Hoffman, 1997) structured around the
two extremes of vaccine design. Efforts to date have focused
primarily on the technology of DNA-based vaccines (Doolan
and Hoffman, 2001; Moorthy and Hill, 2002). First-generation
DNA vaccines have proved suboptimal, but a number of
immune-enhancement strategies show promise, at least in
animal models. Most impressive are heterologous prime/boost
approaches with DNA, recombinant viruses or recombinant
protein in adjuvant, which show great potential for the
induction of high levels of T cell or antibody responses, and
protection (reviewed in Schneider et al., 1999; McConkey et
al., 2003; Dunachie and Hill, 2003). 
A major shortcoming of this approach is that it is based on
a limited panel of already well-characterized antigens that may
or may not be the most optimal targets of protective immunity
(if, in fact, all antigens are not created equal). Additional, and
potentially more promising, antigens could be included once
identified. Regardless, in order for the vaccine to be effective
in genetically diverse host populations and against all
antigenically distinct P. falciparum strains, sufficient diversity
must be represented by the panel of antigens to ensure that
multiple arms of the immune system are activated and to allow
for overcoming or circumventing the genetic restriction of the
host immune response and the polymorphism of critical target
epitopes. Finally, this vaccine approach and the number of
antigens that can be targeted will be limited by logistical
considerations regarding the size of the insert that can be
included in a given vaccine delivery system and the number of
antigens that can be formulated or administered simultaneously
in the absence of antigenic competition (Sedegah et al., in
press), as well as by manufacturing considerations. 
An alternative approach, designed to mimic whole-
organism-induced protective immunity
Despite considerable efforts over the past decades to develop
subunit malaria vaccines that provide protective immunity
comparable to that conferred by the human models of
irradiated sporozoite immunization and naturally acquired
immunity, no vaccine candidate has proven sufficiently
efficacious to warrant commercial development (reviewed in
Richie and Saul, 2002). This may not be too surprising given
that the current generation of subunit vaccines is based on a
single or few antigens and therefore might elicit too narrow a
breadth of response and provide neither optimal protection nor
protection on genetically diverse backgrounds. Moreover,
responses against characterized antigens, known to be
D. L. Doolan and others
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expressed in the hepatic stage of the Plasmodium life cycle and
recognized by CD4+ and CD8+ T cells, that are induced by
sporozoite immunization are not as robust as those induced by
subunit vaccination and seem unable to account for the
protection seen with whole-organism vaccination (Sedegah et
al., 1994; D. L. Doolan and C. Dobano, unpublished results).
This suggests that the protective immunity induced by
irradiated sporozoite immunization is due to the summation of
many immune responses of low magnitude against multiple
targets, where the low magnitude of response is a result of the
low density of epitope presentation inherent in the process.
Similarly, the magnitude of antibody responses against
candidate blood-stage vaccine antigens or whole parasites
induced by natural exposure to malaria is modest, and in many
instances lower than the levels induced by subunit vaccination
(Holder, 1996; Berzins and Perlmann, 1996; Brown and
Rogerson, 1996). Overall, these data support the contention
that immunization with only one or a few parasite proteins will
be unlikely to duplicate the broad and sustained immunity
elicited by exposure to a parasite that has thousands of proteins. 
We believe that the sterile immunity achieved after
immunization with irradiated sporozoites is probably directed
against a large number of proteins expressed by irradiated
sporozoites in hepatocytes and against a number of epitopes
on those proteins and that the naturally acquired immunity
experienced by those living in endemic areas is probably
directed against a large number of proteins expressed on the
surface of merozoites or infected erythrocytes or in apical
organelles. Small or modest immune response against tens,
hundreds or thousands of parasite proteins may be additive
or synergistic. We are working, therefore, towards the
development of a new generation vaccine, based on the
presumption that duplicating and sustaining the protective
immunity induced by whole-organism vaccination may require
a vaccine that mimics the complexity of the organism itself,
incorporating antigens from multiple stages and accounting for
the extraordinary diversity of natural parasite populations. This
approach requires the identification of an unprecedented
number of parasite-derived proteins, the minimal CD8+ and
CD4+ T cell epitopes on those antigens, and development of
a vaccine delivery system that reproduces the breadth and
multiplicity of the whole-organism-induced protective
immunity. Our strategy is to focus on the two human models
of whole-organism-induced immunity – irradiated sporozoite
immunization and naturally acquired immunity – and to
systematically identify and prioritize the antigens in the
Plasmodium parasite targeted by the different immune
responses. The central assumption is that, of the ~5300
potential proteins in the P. falciparum genome (Gardner et al.,
2002), there will be one subset that is the target of protective
T cell responses directed against the proteins expressed by the
liver-stage parasite (those antigens expressed by irradiated
sporozoites in hepatocytes) and another subset that is the target
of protective antibody responses (those antigens expressed on
merozoites, on infected erythrocytes and in apical organelles).
We also anticipate that results of genome-based studies will
suggest a prioritization amongst these antigens, according to
their relative magnitude of immune reactivity and presumed
protective capacity.
The P. falciparum genome and proteome – the foundation
for a ‘Genomes-to-Vaccines’ approach
In 1996, an international consortium of genome scientists
and funding agencies was formed to sequence the genome of
P. falciparum. It was anticipated that the data deriving from
this and related projects would facilitate the development and
fielding of effective interventions against malaria, including
vaccines, drugs and diagnostics (Wirth, 2002). To provide
access to the data and to the bioinformatics tools necessary for
data mining, the consortium established a centralized web-
based database, ‘PlasmoDB’ (http://www.plasmodb.org), for
the collection, annotation and analysis of genomic sequence
data, proteomic data, gene and protein expression data, single
nucleotide polymorphism (SNP) and expressed sequence tag
(EST) data sets, genetic data and other information relevant to
genomics-based research (Bahl et al., 2003).
The genomic sequence of P. falciparum was completed and
published in October 2002 (Gardner et al., 2002). The P.
falciparum proteome represented by stage-specific sporozoites,
merozoites, trophozoites and gametocytes was also elucidated
using MudPIT, which combines in-line high-resolution liquid
chromatography and tandem mass spectroscopy (Washburn et
al., 2002), and was published simultaneously with the P.
falciparum genome (Florens et al., 2002; Lasonder et al.,
2002). Since then, additional erythrocyte-surface-expressed
parasite proteins have been identified using high-throughput
proteomics (L. Florens, X. Liu, Y. Wang, O. Yang, O.
Schwartz, M. Peglar, D. J. Carucci, J. R. Yates, III, Jr and
Y. Wu, manuscript submitted). More recently, the gene
expression profile of the P. falciparum parasite during the
different stages of the parasite life cycle has been completed
(LeRoch et al., 2003). Putative hepatic-stage-specific proteins
have also been identified through EST sequencing, additional
proteomics studies and bioinformatic methods (J. Aguiar,
unpublished; P. L. Blair, unpublished; L. Florens,
unpublished). In total, these data provide a set of open reading
frames (ORFs) corresponding to potential P. falciparum target
antigens and evidence for expression of these genes in different
stages of the parasite life cycle. This foundation can be
exploited for the identification and prioritization of novel
antigens and epitopes that may be targets of anti-malarial
protective immunity.
The genomic sequences of a number of other human, monkey
or rodent Plasmodium spp. used in vaccine or drug development
research, including a P. falciparum clinical isolate, P. vivax, P.
knowlesi, P. reichanowi, P. yoelii (Carlton et al., 2002), P.
chabaudi and P. berghei, have been also determined or are in
progress (Hoffman et al., 2002b; http://www.tigr.org). The
complete genomic sequence of the human host (Venter et al.,
2001; Lander et al., 2001) and the Anopheles gambiae mosquito
vector (the most important vector of P. falciparum
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in sub-Saharan Africa; Holt et al., 2002) are now also available.
The hope is that these data sets will facilitate additional
characterization of those P. falciparum antigens for which a
monkey or mouse orthologue is identified and will allow for
comparative genomics (Thompson et al., 2001; Waters, 2002)
and other studies designed to characterize Plasmodium spp.
parasite antigens and their biological function relative to the
insect or vertebrate host or to identify potential avenues for the
development of novel interventions (Wirth, 2002). However, the
promise of these multiple genomic data sets cannot be fully
realized without developing appropriate technologies for
systematically converting genomic data into protective vaccines,
drugs or diagnostics. 
Platform technologies for P. falciparum Genomes-to-
Vaccines
Despite the completion or impending completion of the
genomic sequence of a large number of pathogens that threaten
public health, there is currently no algorithm that can be used
effectively to identify the target antigens or epitopes of
protective T cell or antibody responses from genomic data.
Furthermore, the identification of antigens that will stimulate
the most effective immune responses against the target
pathogen is problematic, particularly when the genome of the
pathogen is large, as is the case for P. falciparum. Accordingly,
we are developing, validating and implementing several
platforms to identify from the P. falciparum proteome (1) the
subset of antigens expressed by irradiated sporozoites within
hepatocytes that are recognized by T cell responses, based on
the irradiated sporozoite model and (2) the subset of parasite
proteins expressed on the surface of merozoites or infected
erythrocytes or in apical organelles that are recognized by
antibody responses, based on the naturally acquired immunity
model. These platforms include: (1) recombinatorial cloning
(Gateway™); (2) transcriptionally active PCR (TAP); (3)
protein arrays and (4) ImmunoSense epitope-based strategies. 
Recombinatorial cloning (Gateway™)
Traditional methods of cloning are too inefficient, laborious
and costly to be applied to P. falciparum. Moreover, the high
adenine/thymine content of the P. falciparum genome results
in a large proportion of clones containing internal deletions and
rearrangements and large numbers of non-recombinant clones.
There is also a need to clone selected ORFs into multiple
vectors, depending on the intended application (DNA
vaccination, protein expression, transfection studies, etc.).
Accordingly, we have evaluated the potential utility of a highly
efficient directional recombinatorial cloning system. The
Gateway™ system (InVitrogen Inc., Carlsbad, CA, USA) is
designed to rapidly and efficiently clone large numbers of
genes into plasmid vectors by exploiting the well-characterized
site-specific recombination between bacteriophage lambda and
Escherichia coli. The recombination process is designed such
that a ‘suicide’ gene in the entry vector (and expression
vectors), which is not able to support bacterial growth on
standard E. coli host cells, must be replaced by the gene of
interest to permit survival, making the plasmid-to-plasmid
cloning essentially 100% effective. Dr Joshua Labaer and
colleagues at the Harvard Institute of Proteomics (Harvard
Medical School, Boston, MA, USA) provided invaluable
assistance in adapting the Gateway™ system for use with P.
falciparum; these researchers have produced a complete set of
more than 7000 Gateway™ clones from Saccharomyces
cerevisiae and a set of clones from the human genome
(Brizuela et al., 2001).
Initially, a set of Gateway™ entry clones and destination
clones in a customized DNA vaccine plasmid (J. C. Aguiar, J.
LaBaer, V. Y. Shamailova, M. Koundinya, J. A. Russrl, P. L.
Blair, F. Huang, K. Strang, W. Mar, R. Anthony et al.,
manuscript in preparation) and in a recombinant protein
expression vector are generated for a prioritized subset of P.
falciparum ORFs. Then, antisera against each of the gene
products are generated in mice and used to establish stage
specificity and subcellular localization (see below; stage-
specific expression) and perhaps inhibitory activity using
functional assays such as the inhibition of sporozoite invasion,
inhibition of liver-stage development or growth inhibition
assays. Capacity of the putative proteins to be recognized by
immune sera from individuals residing in malaria-endemic
areas or T cells from irradiated-sporozoite-immunized
volunteers can also be evaluated (see below; immune
screening). 
Proof-of-principle studies with a subset of 111 full-length
single exon genes (J. C. Aguiar, J. LaBaer, V. Y. Shamailova,
M. Koundinya, J. A. Russrl, P. L. Blair, F. Huang, K. Strang,
W. Mar, R. Anthony et al., manuscript in preparation)
demonstrated that more than 86% of ORFs were cloned into
entry and DNA vaccine vectors, in the absence of sequence
deletions or rearrangements, and that antibodies that recognized
P. falciparum merozoites, sporozoites and gametocytes could
be generated by in vivo immunization with the Gateway™-
compatible DNA vaccines. These data establish the Gateway™
as a platform technology for exploiting P. falciparum genomic
data for vaccine development. 
In a parallel project, we are applying the Gateway™ system
to the Plasmodium yoelii rodent model. The goal is to identify
and characterize P. yoelii antigens that can protect against P.
yoelii sporozoite challenge. The underlying assumption is that
P. falciparum orthologues of such antigens would represent
good candidate vaccine antigens. This project focuses on data
from the recently completed genomic sequence of P. yoelii
yoelii (17XNL; Carlton et al., 2002). Selected ORFs, predicted
to be expressed in the sporozoite/liver stage, are cloned using
approaches analogous to those established for P. falciparum.
Inbred BALB/c mice are immunized with pools of plasmids
and challenged with infectious P. yoelii sporozoites. The
capacity of the gene to reduce liver-stage parasite burden is
quantified using Taqman® RT-PCR (Witney et al., 2001).
Plasmid pools associated with protection are then
deconvoluted to identify the individual protective genes. The
advantage to the pooled plasmid approach is that it offers a
D. L. Doolan and others
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higher probability of a positive outcome, given that DNA
vaccines based on single antigens may not necessarily be
capable of conferring a high degree of protection against
parasite challenge and that the protection induced by the multi-
antigenic Plasmodium sporozoite may reflect the summation
of immune responses directed against a relatively large number
of parasite antigens. Preliminary studies with 192 single exon
ORFs selected from a P. yoelii sporozoite EST library (Kappe
et al., 2001), with 19 of the 192 being evaluated in vivo to
date, have established proof-of-principle for this approach
(D. Haddad, E. Bilcikova and W. R. Weiss, manuscript in
preparation). 
The primary outcome of the P. yoelii studies is protection
rather than immunogenicity (although we recognize the value
in correlating results of in vitro immunological screening
assays with in vivo protection). This is a major advantage in
the context of vaccine development, since in vivo identification
of protective antigens is not feasible in the P. falciparum
system prior to clinical testing, and potentially protective P.
falciparum antigens may be identified by extrapolation from
the P. yoelii system. It should be recognized, however, that the
demonstration that a P. yoelii antigen is capable of protecting
against P. yoelii sporozoite challenge in a mouse model does
not necessarily mean that its P. falciparum orthologue would
protect against P. falciparum parasite challenge in humans. An
additional confounder is that the P. yoelii studies are carried
out in a single genetically homogeneous inbred mouse strain
(BALB/c; H-2d) whereas the target population for a P.
falciparum vaccine is a genetically heterogeneous outbred
human population. Nonetheless, mouse models are generally
considered as suitable animal models for malaria vaccine
development (Renia et al., 2002; Sanni et al., 2002), and P.
falciparum orthologues of all characterized and protective P.
yoelii antigens are currently considered high priority vaccine
candidates. 
Transcriptionally active PCR (TAP)
With the Gateway™ system, transcriptionally active genes
are created by cloning the gene of interest into a replication-
competent expression vector, transforming and growing
bacteria and then purifying the plasmid. Even given the
efficient nature of the recombinatorial approach as compared
with traditional cloning methods, this approach is time, labor
and cost prohibitive if a large number of genes needs to be
analyzed. Genome-wide screening is also limited by the ability
to validate that the appropriate recall immune responses can be
induced against identified targets.
One solution is to render PCR products transcriptionally
active (Sykes and Johnston, 1999). In response to this need, Dr
Philip Felgner and colleagues (Gene Therapy Systems Inc.,
San Diego, CA, USA) developed a technology called
transcriptionally active PCR, which allows for rapid and
efficient generation of hundreds or thousands of genes in a
form that is transcriptionally active in vitro and in vivo and that
therefore can be used for high-throughput functional screening
on a genome-wide basis (Liang et al., 2002). The technology
uses nested PCR, in which two or more DNA fragments can
be joined in a desired orientation, to introduce functional
promoter and terminator sequences onto the gene of interest.
Additionally, the technology can be modified by adding either
epitope-tags (influenza-HA) or mammalian [cytomegalovirus
(CMV)] or prokaryotic (bacterial phage T7) promoters.
Epitope-tagging facilitates detection and characterization of
the protein by western blot, enzyme-linked immunosorbent
assay (ELISA), immunocytochemistry and fluorescence-
activated cell sorting (FACS). Adding a T7 promoter allows
for the generation of gene-specific mRNAs in a cell-free
system and the generation of proteins in a cell-free
transcription/translation system. The TAP system therefore
offers enormous potential for genome-wide screening. To
assess immunological potency, for example, TAP fragments or
TAP proteins can be screened in novel cellular or humoral
assays to quantify the capacity of each antigen to induce recall
cellular or humoral immune responses from malaria-immune
individuals (see below; immune screening assays).
Using a panel of already well-characterized P. falciparum
and P. yoelii antigens, as well as a limited panel of ORFs
selected from the P. falciparum genomic sequence database,
we have evaluated the potential of TAP in the context
of Plasmodium (D. A. Regis, P. Quinones-Casas and D. L,
Doolan, manuscript in preparation). We have identified
conditions for the efficient amplification of all P. falciparum
and P. yoelii genes from either genomic DNA or plasmid DNA
template and have established that Plasmodium-derived TAP
fragments can be expressed in vitro and in vivo and are
immunogenic in mice. We are currently developing and
validating cellular and humoral immune screening assays
based on TAP technology (see below; immune screening). 
Protein arrays
Recognition of the less than perfect correlation between
RNA and protein expression (Gygi et al., 1999) and the
influence of post-translational modification of proteins on
phenotypic and functional outcome, including recognition
by the host immune system, highlights the importance of
genome-wide screening based on the translated products of the
gene sequences. Cell-free gene transcription and translation
systems, which couple T7 RNA polymerase-driven
transcription with translation, offer the potential for high-
throughput protein production. Dr Philip Felgner and
colleagues at the University of California, Irvine (Irvine, CA,
USA) have adapted the cell-free transcription and translation
system to a high-throughput protein expression platform using
a robotics workstation, enabling 384 different purified proteins
to be produced and purified in a single day. In collaboration
with Dr Felgner, we are applying protein array technology for
functional screening of the P. falciparum genome.
The P. falciparum proteome will be prepared in two forms.
The first form will be on protein ‘chips’, and the chips will be
used to quantify serum antibody titers from immune or semi-
immune humans against each of the target ORFs. The arrays
will be screened for capacity of the target antigens to be
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recognized by sera collected from clinically distinct cohorts of
individuals naturally exposed to malaria. For the second
proteome format, each individual protein will be purified and
stored in 96-well microtiter plates in a form that will enable
them to be delivered to, and processed by, antigen-presenting
cells (APCs). These APCs will then be used as targets for in
vitro cellular assays to evaluate the capacity of each putative
protein to be recognized by recall T cell responses from
irradiated-sporozoite-immunized volunteers. It is anticipated
that this quantitative array-based humoral and cellular immune
response scan will provide a profile of immune responses
against P. falciparum in humans. 
ImmunoSense
The approaches detailed above are aimed at identifying the
complement of P. falciparum antigens targeted by protective
T cell and/or antibody responses. The ImmunoSense approach
offers the opportunity to simultaneously identify the target
antigens as well as the minimal epitopes on those antigens. It
is an integrated approach (executed in collaboration with Dr
Alessandro Sette and colleagues, La Jolla Institute of Allergy
and Immunology, San Diego, CA, USA) that incorporates
bioinformatic predictions, human leukocyte antigen (HLA)
supertype considerations, high-throughput binding assays and
cellular assays. In essence, it represents a process in which
epitope predictions are utilized in ‘reverse’, as a tool to identify
new antigens; epitope identification has thus far been seen only
as a means to identify the epitopes contained within a protein
considered as a target of cellular immunity. 
A detailed description of the ImmunoSense approach, and
its application in the malaria model, has been reported
elsewhere (Doolan et al., 2003). In brief, amino acid sequences
corresponding to the subset of Plasmodium sporozoite/liver-
stage ORFs are scanned using allele-specific computerized
algorithms for peptide epitopes predicted to bind with high
affinity to Class I and Class II HLA supertypes. HLA
supertypes are characterized by largely overlapping peptide
repertoires and are expressed at high frequencies in all major
ethnicities (Southwood et al., 1998; Sette and Sidney, 1998,
1999). Pools of peptides, each pool representing a putative
antigen, are screened for immune reactivity by assays such
as IFN-g ELISPOT (enzyme-linked immunospot), using
peripheral blood mononuclear cells (PBMCs) from individuals
immunized with radiation-attenuated P. falciparum
sporozoites or mock-immunized controls. Peptide pools that
recall strong T cell responses are deconvoluted to identify the
individual peptide epitopes that are recognized. These antigens
and epitopes can be prioritized according to the magnitude of
the recall response and their capacity to be preferentially
recognized by protected versus non-protected volunteers, as
well as by their ability to bind strongly to multiple members
of the relevant superfamily.
We have validated this approach in the context of P.
falciparum (Doolan et al., 2003). Starting with 27 ORFs thought
to be expressed in the sporozoite proteome, we identified 16
novel proteins reproducibly recognized by irradiated-
sporozoite-immunized volunteers. Nine antigens were highly
antigenic (recognized by >50% of volunteers in >25% of
assays), three antigens were of intermediate reactivity, and four
were of low reactivity (Doolan et al., 2003). Significantly, a
number of antigens identified using this strategy were more
antigenic than well-characterized antigens currently considered
the best vaccine candidate antigens. These experiments provide
proof-of-concept for the Immunosense approach, thereby
allowing for more comprehensive genome-wide analysis. 
The anticipated outcome of these studies will be (1) the
identification, from the complete P. falciparum proteome, of
those proteins that correspond to immunodominant antigens
recognized by volunteers immunized with radiation-attenuated
P. falciparum sporozoites and their minimal target epitopes
and (2) the prioritization of those antigens and epitopes on the
basis of immune reactivity and according to their potential
association with protection against P. falciparum sporozoite
challenge. Additionally, it is expected that the studies will
establish whether protective immune responses in humans
immunized with irradiated P. falciparum sporozoites are
narrowly focused on a few immunodominant antigens and
epitopes or, alternatively, are broadly dispersed on a relatively
large number of parasite antigens.
Selection and prioritization of P. falciparum ORFs for
genome-wide screening by Genomes-to-Vaccines
approaches
The complexity of the 23·Mb P. falciparum genome
parasite, with an estimated 5268 predicted proteins (Gardner
et al., 2002), dictates a rational approach to prioritize ORFs
representing putative antigens for evaluation. Bioinformatics is
recognized as an essential tool for mining genomic and
proteomic databases. However, there is currently no algorithm
that can be used to identify the targets of protective antibody
or T cell responses from genomic sequence data. In the case
of antibody responses, one approach has been to focus on
predicted surface or secreted molecules presumably accessible
to antibody, but there has been no systematic genome-wide
validation of the accuracy of such predictions. In the case of T
cell responses, the subcellular location and function of the
target protein is less important than the presence of appropriate
MHC-binding epitopes in the sequence. Plasmodium gene-
predicting algorithms such as Glimmer M or Phat
(http://www.tigr.org/softlab/glimmer) can be used to identify
genes, exons and introns; programs such as Simple Modular
Architecture Research Tool (SMART) (http://smart.embl-
heidelberg.de) can identify structural and functional domains;
TMHMM2 can predict transmembrane domains; SignalP can
predict signal peptides; Prospero can predict repetitive regions;
and BLAST can identify orthologous sequences amongst
different Plasmodium species. A range of bioinformatics tools
can be accessed via the PlasmoDB database (http://www.
plasmodb.org) or via the web (e.g. http://www.epitope-
informatics.com/References.htm#BcellEpitopes).
Other experimentally derived data can also be considered,
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such as the relative level of expression of the gene or the
corresponding protein or the degree of polymorphism as
indicated by SNP analysis. For example, one outcome of the
MudPIT analysis of P. falciparum sporozoites (Florens et al.,
2002) is a database detailing the number of MudPIT runs in
which corresponding peptides were identified, the number of
peptide hits per protein, the percentage of the protein sequence
covered by those peptides, and the unique locus identifier of
the corresponding genomic sequence. ORFs within this data
set can therefore be ranked according to their relative level of
expression in the sporozoite proteome. Similarly, information
regarding stage-specific gene expression is also available, as a
result of AffyMatrix gene chip studies (LeRoch et al., 2003).
Correlation between protein expression and gene expression
data sets is currently in progress (J. R. Yates and E. Winzeler,
personal communication).
Despite this wealth of information, and in the absence of
genome-wide validation, it is not obvious which tools are the
most appropriate and which criteria are the most valid for ORF
selection in the context of vaccine development. We have
elected to use a combination of bioinformatics and comparative
genomics approaches based on a number of genomic,
proteomic, gene expression and other large-scale Plasmodium
functional genomic data sets to select and prioritize P.
falciparum ORFs for genome-wide screening.
One approach (based on the irradiated sporozoite model) has
been to combine transcription and proteome analyses, using
sequences derived from a P. yoelii sporozoite EST database
(Kappe et al., 2001), P. falciparum sporozoite EST database (J.
C. Aguiar, J. LaBaer, V. Y. Shamailova, M. Koundinya, J. A.
Russrl, P. L. Blair, F. Huang, K. Strang, W. Mar, R. Anthony et
al., manuscript in preparation), complete P. falciparum genome
expression profiling using gene chips (Le Roch et al., 2003) and
proteome analyses (Florens et al., 2002; Lasonder et al., 2002).
Potential Plasmodium liver-stage-specific expressed genes were
down selected by comparing P. falciparum orthologues of a P.
yoelii laser capture microdissected liver-stage library (Sacci et
al., 2002) with annotated genes not present in current EST
libraries and not possessing peptide matches in P. falciparum
proteome analyses. Selected antigens were further examined and
ranked using the PlasmoDB web-based database for predicted
signal sequences and transmembrane domains (for sporozoite
antigens only), Pfam and GO assignments, sequence similarities
and exon/intron gene structure. These criteria led to a
manageable set (~250 annotated genes) of putative vaccine
targets for study (representing ~5% of the P. falciparum
genome; P. L. Blair, unpublished results). Selected ORFs can
then be subjected to an automated primer design algorithm, such
as a Primer3 (White Head Institute, Cambridge, MA, USA), for
predicting oligonucleotide primer pairs suitable for high-
throughput cloning using the Gateway™ technology or other
Genomes-to-Vaccines approaches. 
Target credentialing
Target credentialing systematically assigns functional
criteria to each protein and, depending on the application,
allows for a reduction of the number of potential targets from
~5300 to a more realistic number for more comprehensive
evaluation and/or to serve as the foundation for the
development of new candidate vaccines, drugs or diagnostics.
Stage-specific expression and subcellular localization
Because the requirement for inducing different types of
immune responses by vaccination depends on the stage during
the parasite’s life cycle at which the protein is expressed,
identification of the stage-specific expression of putative
antigens is critical. MudPIT analysis of different preparations
of parasite material (e.g. sporozoites, merozoites, trophozoites,
gametocytes; Florens et al., 2002; Lasonder et al., 2002)
provides evidence for expression of putative proteins in the
different stages of the parasite’s life cycle but not relative
expression between the different stages. Comprehensive gene
expression data sets (Le Roch et al., 2003) provide information
on expression of all ORFs within any given stage as well
as between stages. P. falciparum DNA microarray studies
(Hayward et al., 2003; Rathod et al., 2002) also provide
information regarding stage-specific expression, but such data
sets are currently limited to only a subset of the P. falciparum
genome. Finally, proteomic analysis and protein structure
prediction algorithms can suggest which proteins are likely to
be membrane-associated surface proteins, but the accuracy of
such predictions has yet to be validated on a genome-wide
scale.
More specific information regarding the stage-specific
expression of putative P. falciparum proteins can be obtained
by screening antigen-specific sera against parasite preparations
(Hoffman et al., 1998). These sera will be generated for those
ORFs evaluated in the Gateway project. However, financial
and logistical reasons preclude comprehensive in vivo
immunization studies for the thousands of putative P.
falciparum proteins in the proteome. Antisera are evaluated by
immunofluoresence antibody tests (IFAT) against stage-
specific slides prepared from P. falciparum sporozoites,
cultured hepatoma cells infected with irradiated or non-
irradiated P. falciparum sporozoites, erythrocytic-stage P.
falciparum parasites from carefully synchronized cultures
corresponding to ring trophozoites, mature trophozoites, and
schizonts or gametocytes. 
Information on the subcellular localization of putative
proteins can also be obtained from the IFAT studies.
Although IFAT does not have the resolution of
immunoelectron microscopy, it is nonetheless possible to
distinguish a number of subcellular localization patterns; for
example, in sporozoites, predominant surface expression
can be distinguished from internal expression associated
with micronemes, a secretory organelle, and, in the
erythrocytic-stage parasites, expression on the surface of
infected erythrocytes, on the surface of parasites within the
red cell, in the apical organelles (micronemes and rhoptries)
and within the parasite cytoplasm can be reliably
distinguished. 
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Immune screening 
In our Genomes-to-Vaccines program, we propose to
identify, from the complete P. falciparum proteome, (1) the
subset of antigens expressed by irradiated sporozoites in
hepatocytes that are recognized by protective T cell responses
and (2) the subset of antigens expressed on the surface of
merozoites or infected erythrocytes or apical organelles that are
recognized by protective antibody responses. A critical
component of our strategy is the evaluation of immune
responses. Standard immunological assays are not suitable for
high-throughput screening with plasmid DNA, PCR fragments
or recombinant proteins. Therefore, we are developing and
optimizing novel cellular and humoral immune assays that can
be applied to genome-wide screening (P. Quinones-Cases and
D. L. Doolan, unpublished results; J. Aguiar and G. T. Brice,
unpublished results).
To identify targets of protective T cell responses, we are
utilizing specimens from irradiated-sporozoite-immunized
volunteers (both protected and not protected against sporozoite
challenge), presuming that the entire repertoire of sporozoite-
induced T cell specificities will be represented in those
individuals. We are focusing on T cell-derived IFN- g as the
primary marker of cellular immunogenicity, since this is
considered to be the most appropriate in vitro marker of pre-
erythrocytic stage protection identified to date (Good and
Doolan, 1999; Plebanski and Hill, 2000). However, where
possible, we will apply information from other studies
designed to identify robust and predictive in vitro marker(s) of
anti-malarial protective immunity; e.g. immunologically
relevant DNA microarray studies with specimens from
irradiated-sporozoite-immunized volunteers (C. Dobano, P.
Quinones-Casas and D. L. Doolan, unpublished results).
To identify the subset of P. falciparum proteins expressed
on the surface of merozoites or infected erythrocytes or in
apical organelles, we are assaying sera from adults with
naturally acquired immunity, since it is presumed that the
entire repertoire of antibody specificities is represented in those
individuals. However, given the complexity of host–parasite
interactions and the variant disease expression based on
epidemiology, transmission dynamics and the genetic
background and age of the host, we also propose to ultimately
analyze the responses of well-characterized cohorts of
naturally exposed individuals with distinct categories of
clinical disease (e.g. severe malaria, mild malaria,
asymptomatic and symptomatic), as well as individuals of
different ages (neonates, infants, children and adults). Sera
from volunteers immunized with radiation-attenuated P.
falciparum sporozoites and collected at different time points
during the immunization and challenge process will also be
evaluated, to provide a kinetic profile of antibody responses to
pre-erythrocytic stage antigens. 
Biological function
One indication as to the value of a putative antigen for
inclusion in a vaccine relates to its biological function, at least
in the case of protective antibody responses where the target
antigen or the critical linear or conformational B cell epitope(s)
on the antigen must be accessible to the antibodies (e.g. surface
or secreted molecules). The biological function of the target
protein is less important in the case of T cell responses, where
the presence of MHC-binding epitope(s) in the sequence and
appropriate processing of the antigen and presentation of the
T cell epitope in the context of the MHC Class I and/or Class
II molecules for recognition by the host immune system is
critical. 
Unfortunately, there are no algorithms to predict how a
given antigen will function in vivo, and there are not yet
established methods to accurately assess biological function
in vivo, particularly in a high-throughput manner. Some
approaches, such as gene-knockout studies (Wickham et al.,
2003), are potentially useful in this regard but are currently not
adapted for genome-wide application. For those putative
proteins where the desired immune effector mechanism is an
inhibitory antibody, however, it is possible to assess biological
activity in vitro. Specifically, the capacity of antigen-specific
antisera to inhibit parasite development or invasion could be
evaluated by the inhibition of sporozoite invasion assay,
inhibition of liver-stage development assay, or growth
inhibition assay. 
Ultimately, the capacity of an individual or pool of
erythrocytic-stage proteins to induce protective antibodies in
vivo could be assessed by immunizing Aotus monkeys with
plasmid DNA or recombinant proteins and challenging with
P. falciparum blood-stage parasites (Collins, 2002).
Demonstration of pre-erythrocytic protection against P.
falciparum 3D7 strain is currently not feasible in animal
models, since a reproducible Aotus–P. falciparum 3D7
sporozoite challenge model is not available, and mice cannot
be infected with P. falciparum. However, reproducible
infection of intact Aotus lemurinus griseimembra monkeys by
intravenous inoculation with sporozoites from a monkey-
adapted P. falciparum strain (Santa Lucia) and a wild-type P.
falciparum strain (Cali-Colombia-4, FCC-4) has been recently
reported (Zapata et al., 2002), allowing for the possibility
of evaluating protection with heterologous P. falciparum
sequences of a given antigen of interest. Also, a reproducible
sporozoite challenge model is available for P. knowlesi in
rhesus monkeys (Collins, 2002; Rogers et al., 2001) and for P.
yoelii in mice (Sedegah et al., 1982), so protection could be
evaluated for those P. falciparum antigens that have identified
as P. knowlesi or P. yoelii orthologues. 
The next step: multi-epitope vaccine development 
How best to mimic the complexity of multi-antigenic whole
organism vaccines by subunit vaccination is not obvious.
Challenges include how to optimally combine multiple
antigens or their epitopes, how to induce the appropriate
responses against each antigen or epitope included in a vaccine
and how to direct immune responses towards antibody
production for some antigens or epitopes and T cell responses
for others. A basic conundrum is that adding antigens to a
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multi-antigen cocktail incrementally reduces the dose of each
component and thus may reduce component immunogenicity
to the point where protection is lost. Finally, for a vaccine to
be optimally effective, it must elicit protective immune
responses that are sustained over time, by boosting after natural
exposure to the parasite or by specific vaccination strategies.
Although progress has been made, no delivery system has yet
been shown to be adequate. It is our contention that, amongst
those vaccine technologies currently available, only multi-
epitope-based approaches offer the potential for delivering a
subunit vaccine that can duplicate the complexity of whole-
organism-induced protection. Including only the protective
epitopes from multiple antigens and discarding all other
extraneous sequence provides an enormous efficiency of space,
probably the only feasible way to package the antigenic
complexity of the parasite as a subunit vaccine.
In other systems, induction of simultaneous responses
against multiple epitopes derived from multiple antigens has
already been demonstrated. The immunogenicity of multi-
epitope constructs appears to be strongly influenced by a
number of different variables, and the immunogenicity (or
antigenicity) of the same epitope expressed in the context of
different vaccine constructs can vary over several orders of
magnitude. This situation underscores the necessity of a
systematic study of different variables in order to establish
clear criteria for the optimal design of multi-epitope vaccines
(reviewed in Sette et al., 2001, 2002). To address this in the
context of malaria, in collaboration with Jeff Alexander, Brian
Livingston, Mark Newman and colleagues (Epimmune Inc.,
San Diego, CA, USA), we are designing and optimizing multi-
epitope vaccines comprising a panel of CD8+ and CD4+ T cell
epitopes derived from four P. falciparum pre-erythrocytic
stage antigens. These epitopes were identified by Class I and
Class II algorithm predictions and peptide binding/recognition
strategies similar to those described above for the
ImmunoSense approach and were recognized by recall
immune responses from volunteers immunized with irradiated
sporozoites or naturally exposed to malaria (Doolan et al.,
1997, 2000). Studies are aimed at optimizing vaccine design
by eliminating junctional epitopes, optimizing spacers between
epitopes and considering the order of epitopes, effect of
flanking regions, and cellular targeting to antigen processing
and presentation pathways. Recognition of individual epitopes
is demonstrated by immunogenicity assays utilizing HLA
transgenic mice and/or antigenicity assays using human APCs
transfected in vitro with the prototype vaccine. The simplest
vaccine configuration capable of effective delivery of the
selected sets of epitopes will also be determined. Subsequent
studies will identify the optimal vaccine delivery strategy for
simultaneous induction of immune responses against multiple
epitopes, and the appropriate vaccine formulation studies.
Overall, it is anticipated that these studies will define
operational rules for the design and optimization of multi-
epitope-based vaccines. 
Finally, we propose to compare the efficacy of the multi-
epitope vaccine with the whole-organism-irradiated sporozoite
vaccine, as well as whole antigen subunit vaccines (DNA and
viral vectored), in vivo in HLA transgenic mice and in vitro in
antigenicity assays using humans APCs. It is anticipated that
these studies will validate the multi-epitope approach beyond
the level of antigen and epitope identification and will provide
important information regarding the potential of multi-epitope-
based approaches to mimic whole-organism-induced
immunity.
Conclusion
The human models of irradiated sporozoite immunization
and naturally acquired immunity suggest that the development
of a malaria vaccine is feasible. We are working toward the
development of a new generation malaria vaccine based on
the presumption that duplicating the protection induced by
the whole organism may require a vaccine approaching the
complexity of the organism itself. We anticipate that the
Genomes-to-Vaccines strategies described above –
GatewayTM recombinatorial cloning, TAP, protein arrays and
ImmunoSense epitope screening – will identify the
complement of P. falciparum antigens recognized by
individuals immunized with irradiated P. falciparum
sporozoites (in the case of T cell responses) or naturally
exposed to malaria (in the case of antibody responses). This
will allow for the design, optimization and evaluation of new
candidate malaria vaccines based either on a limited number
of antigens and/or epitopes that are more immunogenic than
those currently available or that include many more antigens
and/or epitopes and therefore may be more effective. Finally,
these data will allow for the development of a vaccine capable
of reproducing the breadth and multiplicity of the whole-
organism-induced protection, by incorporating an
unprecedented number of parasite-derived proteins or their
minimal epitopes that are targets of protective immune
responses. It is our contention that the whole genome approach
proposed here will probably be much more successful than
other approaches in combating the complex Plasmodium
parasite and that significant and long-term impact on public
health may be achieved only by exploiting the enormous
opportunities provided by sequencing the Plasmodium
genome.
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